NCT07332338

Brief Summary

REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 29, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 12, 2026

Completed
Last Updated

March 23, 2026

Status Verified

March 1, 2026

First QC Date

December 29, 2025

Last Update Submit

March 18, 2026

Conditions

Post-COVID-19 ConditionPost-COVID ConditionPost-COVID SyndromeLong COVIDChronic FatigueChronic Fatigue SymptomsFatigue Post Viral

Keywords

Long COVIDPost-COVID syndromePost-COVID conditionUmbilical cord bloodREGENECYTEPost-COVID fatigueChronic fatigue symptomsFatigue post viral

Interventions

REGENECYTE®BIOLOGICAL

HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female aged ≥ 18
  • With post-COVID condition
  • Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)
  • Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE
  • Able to provide signed informed consent (by the subject or his/her legally authorized representative)
  • Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent

You may not qualify if:

  • Neurological disorders prior to COVID-19 diagnosis
  • With pre-existing terminal illness
  • With known immune disease
  • Is pregnant or breastfeeding
  • Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening
  • Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period
  • Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases
  • Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

D&H National Research Center #1

Miami, Florida, 33169, United States

AVAILABLE

Myrak Research Center Inc.

Miami Lakes, Florida, 33014, United States

AVAILABLE

MeSH Terms

Conditions

Post-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

COVID-19Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Clinical Research Department

CONTACT

886-2-26013013expandedaccess@stemcyte.com

StemCyte, Inc.

CONTACT

866-389-4659expandedaccess@stemcyte.com

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 29, 2025

First Posted

January 12, 2026

Last Updated

March 23, 2026

Record last verified: 2026-03

Locations

US(2)